Hemophilia A Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hemophilia A Epidemiology Forecast Report Coverage

Expert Market Research's “Hemophilia A Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hemophilia A. It projects the future incidence and prevalence rates of hemophilia A cases across various populations.  The study covers age and type as major determinants of the hemophilia A population. The report highlights patterns in the prevalence of hemophilia A over time and projects future trends based on multiple variables.

Hemophilia A Understanding: Disease Overview

Hemophilia A is a rare X-linked recessive condition caused by a deficiency or absence of clotting factor VIII (FVIII). It primarily affects males, while females are typically carriers. People with hemophilia A are susceptible to spontaneous bleeding episodes and prolonged bleeding after injuries, surgery, or dental work. Common symptoms include easy bruising, joint swelling, and internal bleeding. Based on the FVIII levels and severity of the bleeding episodes, hemophilia A is classified as severe, moderate, and mild. Severe hemophilia A cases are reported to be characterized by frequent spontaneous bleeding into muscles and joints.

Hemophilia A Epidemiology Perspective 

The hemophilia A epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemophilia A epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Hemophilia B and its trends. The hemophilia A detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Global estimates indicate that hemophilia A ranks as the most common X-linked hereditary disorder of hemostasis, with over 400,000 males  affected by the condition. 
• According to the Centers for Disease Control and Prevention (CDC),  hemophilia A occurs 3 to 4 times more commonly than hemophilia B.
• According to registry data , there were 9,316 people living with hemophilia A in the United Kingdom in 2022/2023, including 2,230 individuals with the severe form of the condition.
• Studies report that hemophilia A accounts for 80% of all hemophilia cases and is estimated to occur in 1 out of 5,000 males .
• As per Orphanet, the prevalence of hemophilia A is reported to be about 1 in 6,000 males , with the condition primarily affecting men. However, it is observed that women may also be symptomatic with a milder clinical presentation of the disease.

Read more about this report - Request a Free Sample

Country-wise Hemophilia A Epidemiology Segment

The hemophilia A epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hemophilia A varies significantly between countries due to differences in genetic backgrounds, socioeconomic and cultural factors, healthcare access, and diagnostic practices. Variations in healthcare infrastructure and awareness also influence reported cases and disease outcomes. As per the Haemophilia and Health Collective of North  (HHCN), India is considered to have the second-largest population of hemophilia patients worldwide, with nearly 136,000 cases of hemophilia A.

Hemophilia A: Treatment Overview

Treatment for hemophilia A is focused on managing bleeding episodes and preventing complications. Factor replacement therapy is the primary treatment approach that replaces the deficient clotting factor. To prevent spontaneous bleeding and joint damage, regular infusion of FVIII concentrates is also used as a prophylactic treatment. Desmopressin (DDAVP) is used for mild hemophilia A, which works by stimulating the release of stored factor VIII from the blood vessels.

Emerging hemophilia A therapeutics, such as gene therapy, are expected to provide a long-term or permanent solution. For instance, in December 2024, the U.S. FDA approved Novo Nordisk's drug, Alhemo,  for preventing or reducing bleeding episodes in hemophilia patients aged 12 and older, particularly those with antibodies against clotting factor replacements.

Key Questions Answered

• What are the key findings of hemophilia A epidemiology in the 8 major markets?
• What will be the total number of patients with hemophilia A across the 8 major markets during the forecast period?
• What was the country-wise hemophilia A epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hemophilia A cases during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hemophilia A during the forecast period of 2026-2035?
• What are the currently available treatments in the global hemophilia A market?
• What are the disease risks, signs, symptoms, and unmet needs of hemophilia A?

Scope of the Hemophilia A Epidemiology Report

• The hemophilia A epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hemophilia B based on several factors.
• The Hemophilia A Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemophilia A report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Global Haemophilia Treatment Market Report and Forecast

Hemophilia B Epidemiology Forecast